leadf
logo-loader
viewBiocept Inc

Biocept inks deal to make its Target Selector cancer assays in-network for 3M US military members, their families

The company worked out a deal with Health Net Federal Services, which manages the TRICARE West health network

US Army members saluting
Biocept is a diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma

Biocept Inc (NASDAQ:BIOC) (FRA:B002) has reached an agreement with Health Net Federal Services, making the firm an in-network provider of the company’s Target Selector liquid biopsy oncology platform.

Health Net provides healthcare services to the TRICARE West (TriWest) regional network, which consists of roughly 3 million US military members and their families. Coverage is available in 21 states.

"It's an honor to become a provider for TriWest and to support the healthcare needs of our country's military service members and their families," CEO Michael Nall, President said in a statement. "Our Target Selector platform can be used to improve treatment outcomes by helping physicians rapidly obtain the actionable information they need to design personalized treatment plans for their patients diagnosed with cancer.

READ: Biocept's newly split-adjusted stock to begin trading on Nasdaq on September 8

Biocept has made expanding its network a priority.

“Expanding the number of managed care agreements is among our strategic objectives. Our liquid biopsy platform is available on an in-network basis to millions of patients across the U.S. and now we are very proud to include those who are serving our country as they fight a new battle, this time with cancer."

Biocept is a diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. It has recently added coronavirus (COVID-19) testing to support efforts to fight the pandemic.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Biocept Inc

Price: 4.43 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $59.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read